Chelsea Therapeutics is committed to developing novel therapeutic agents that address disease states that correspond to significant unmet medical need.
Our pipeline also includes a library of metabolically inert antifolate medications, including a clinical-stage product, CH-4051, for the treatment of rheumatoid arthritis and other autoimmune diseases.
OUR R&D PIPELINE
|Compound||Indication||Phase I||Phase II||Phase III||NDA Submitted|
|Droxidopa||Symptomatic Neurogenic Orthostatic Hypotension|